Abstract: A medical image processing device acquires a user operation. The medical image processing device specifies, from a three-dimensional medical image in which one or more organs appear, an organ of interest to which to apply information. The medical image processing device applies predetermined information to the organ of interest that has been specified. The medical image processing device controls a display device so as to display the three-dimensional medical image.

Abstract: The present invention relates to materials and methods for creating and maintaining a cereal plant line for the production of a hybrid cereal plant, that include for example, and not limitation, using the BLue Aleurone (BLA) system.

Abstract: A workpiece processing apparatus comprises a base member, a slider located above the base member and a punch projecting downward from the slider. The base member is formed with a hydraulic chamber fillable with liquid. The hydraulic chamber has a workpiece processing chamber and a hydraulic-pressure generation chamber which are coupled together. Each of the workpiece processing chamber and the hydraulic-pressure generation chamber extends in the upper-lower direction and opens upward. The base member comprises a piston which is partially received in the hydraulic-pressure generation chamber. When the slider is moved downward, the punch is moved downward and presses the workpiece into the workpiece processing chamber, and the piston receives a downward force and is moved downward. The thus-moved piston increases hydraulic pressure of the liquid.

Abstract: Recombinant Norovirus Virus-Like Particles (VLPs) formed from recombinant Norovirus VP1 proteins, and methods of their use and production are disclosed. In several embodiments, the Recombinant Norovirus VLPs can be used to generate an immune response to Norovirus VP1 protein in a subject. In additional embodiments, an effective amount of the recombinant Norovirus VLPs can be administered to a subject in a method of inhibiting a Norovirus infection.

Abstract: A workpiece processing apparatus comprises a base member formed with a hydraulic chamber fillable with liquid, a punch and a piston. The hydraulic chamber has a workpiece processing chamber and a hydraulic-pressure generation chamber. The punch is movable between an initial position which is apart from the workpiece processing chamber and a received position at which the punch is partially received in the workpiece processing chamber. When the punch is moved from the initial position to the received position, the punch presses the workpiece into the workpiece processing chamber. The piston is partially received in the hydraulic-pressure generation chamber and receives a pressing force directed into the hydraulic-pressure generation chamber in a course of movement of the punch from the initial position to the received position, and the piston is moved in accordance with the pressing force and increases hydraulic pressure of the liquid.

Abstract: Antibodies exhibiting a specific genetically modified signature associated with certain diseases of the central nervous system, like multiple sclerosis (MS) and clinically isolated syndrome have been identified. These antibodies recognize and bind with certain tissues in the brain and central nervous system and thus are useful as therapeutics, in the production of animal disease models, targets for therapies and as part of assays of the central nervous system.

Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.

Abstract: Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13R?2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13R?2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Abstract: A cell culture microdevice for maintaining and culturing a cell therein comprising a cell culture unit having at least a first cell carrier unit defining a cell culture chamber formed therein, the first cell carrier unit formed from at least, a chamber base shaped to support the cell thereon, and one or more chamber walls having one or more chamber wall surfaces enclosing the cell culture chamber about a chamber boundary, the first cell carrier unit further providing a guiding surface to guide instruments or fluids into the cell culture chamber located at an aperture through a chamber wall, wherein the cell culture microdevice is configured at a scale to substantially enclose a single cell or cell mass therein. Embodiments of the cell culture microdevice may be suitable for in vitro fertilisation procedures and drug efficacy testing.

Abstract: Disclosed herein are methods of making pure chalcogenide (e.g., selenium, tellurium, or selenium/tellurium) nanoparticles by irradiating chalcogenide pellets by nano-second laser ablation using chitosan as a capping agent to form chitosan chalcogenide nanoparticles (CS-CgNPs). CS-CgNPs and methods of using such particles are also disclosed herein, such as antimicrobials and antimicrobial coatings effective against biofilms.

Abstract: Tracer eluting proppants, such as proppants that have polymeric coatings on them that include tracers, such as a fluorescent dye. The tracer eluting proppants can comprise proppant particles coated with a polymeric coating that can elute tracer under some, but not all conditions. For example, the tracer can be eluted at elevated temperature, pH, and/or salinity conditions, but not elute at lower temperature, pH, and/or salinity conditions. Methods of making and using tracer eluting proppants are also disclosed, including methods for characterizing subterranean reservoirs.

Abstract: Curable rubber compositions that include reactive ionic surfactants as reinforcing fillers are described, as well as methods for preparing composite rubber compounds by direct addition of ionic surfactant solutions into rubber latex.

Abstract: Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOL or MOP. Also described are methods of using MOLs and MOPs in photodynamic therapy, X-ray induced photodynamic therapy (X-PDT), radiotherapy (RT), radiodynamic therapy, or in radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator.

Abstract: A Pb-free Sn-halide Perovskite solar cell with improved photoelectric conversion efficiency is provided. A solar cell uses a perovskite compound represented by ABX3 where A is a cation, B is a metal, and X is a halogen, wherein each of A, B and X may be composed of a plurality of elements, and B includes Sn and Ge.

Abstract: In some aspects, provided herein are antimicrobial compositions comprising partially esterified polygalacturonic acid and certain fatty acids (e.g., caprylic acid). In some embodiments, the antimicrobial composition may be administered (e.g., topically or orally) to a subject, such as a human patient to treat an infection (e.g., an infection comprising a biofilm). In some aspects, improved catheters are provided.

Abstract: Disclosed herein are various optimized nucleic acids encoding the fukutin-related protein (FKRP). Recombinant vectors comprising the optimized nucleic acid (e.g. operatively linked to a muscle specific promoter), such as recombinant adeno-associated virus vectors, for expressing the protein (e.g. in skeletal and cardiac muscle), and therapeutic compositions contains the vectors are also disclosed. Therapeutic methods of administration of the vectors to a subject for the treatment of a subject with a dystroglycanopathy disorder (e.g., limb-girdle muscular dystrophy 2I) are also disclosed.

Abstract: The current disclosure provides compositions and methods for treatment and prevention of a coronavirus infection. Certain aspects are directed to lipid vesicles comprising SARS-CoV-2 spike protein or a portion or variant thereof. Further aspects include methods for treatment or prevention of a coronavirus infection comprising providing a lipid vesicle comprising a therapeutic protein, such as SARS-CoV-2 spike protein or ACE2. In some embodiments, the disclosed lipid vesicles are useful for targeted delivery of anti-viral therapeutic agents.

Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a primary dose-limiting side effect caused by antineoplastic agents, such as paclitaxel. This causes damage to peripheral nerves and the dorsal root ganglia (DRG). Currently, there are no effective treatments for CIPN, which can lead to long-term morbidity in patients and survivors. Neuronal-immune interactions occur in CIPN and have been implicated both in the development and progression of the disease and disease resolution. The inventors investigated the potential role of Inducible co-stimulatory molecule (ICOS) in the resolution of CIPN. ICOS is an immune checkpoint molecule that is expressed on the surface of activated T cells and promotes proliferation and differentiation of T cells. They found that intrathecal administration of ICOS agonist antibody (ICOSaa) alleviates mechanical hypersensitivity caused by paclitaxel and facilitates the resolution of pain in female mice without a clear benefit in male mice.